Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Renal Cell Carcinoma
Clinical trial register · United States · industry-sponsored

Renal Cell Carcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 19 New York 10 Florida 10 Massachusetts 9 Georgia 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Renal Cell Carcinoma trials in the USA

27 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Nebraska, New York, Ohio
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Active, closed
Shanghai Henlius Biotech
Phase 1
174
California, Florida, Texas, Washington
2025-09-26
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Not yet open
Power Life Sciences Inc.
Observational
500
California
2024-11
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
Nammi Therapeutics Inc
Phase 1
100
California, Colorado, Georgia, New York, Texas, Wisconsin
2024-08-28
Recruiting
HiberCell, Inc.
Phase 1
80
Arizona, California, Colorado, Connecticut, Michigan, Minnesota, Missouri, New York
2024-04-29
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas
2024-04-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
Active, closed
Hoffmann-La Roche
Phase 2
199
Alabama, California, Georgia, Maryland, Tennessee, Texas
2023-04-21
Active, closed
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Janux Therapeutics
Phase 1
130
California, Georgia, Illinois, Michigan, Missouri, New York, North Carolina, Ohio
2023-04-19
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
60
District of Columbia, Illinois, Massachusetts, Utah
2022-08-10
Active, closed
HiFiBiO Therapeutics
Phase 1
72
Arizona, California, Florida, Minnesota, Missouri, Texas, Virginia
2022-03-10
Recruiting
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
VastBiome
Observational
800
Kentucky
2021-11-22
Recruiting
Simcha IL-18, Inc.
Phase 1/2
316
Arizona, Colorado, Connecticut, Florida, Massachusetts, New York
2021-08-06
Active, closed
Daiichi Sankyo
Phase 1
179
Arizona, Colorado, Florida, Oklahoma, Tennessee
2020-12-22
Active, closed
Exelixis
Phase 3
855
California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts, Michigan
2019-06-25
Active, closed
Bristol-Myers Squibb
Phase 3
437
District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina
2019-06-21
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Exelixis
Phase 1
325
California, Florida, Georgia, Iowa, Kansas, Maine, Maryland, Massachusetts
2019-03-20
Recruiting
Xynomic Pharmaceuticals, Inc.
Phase 3
413
Arizona, California, Kentucky, Louisiana, Nebraska, New York, Ohio, Oregon
2018-07-17
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
Exelixis
Phase 1
914
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2017-09-05
Active, closed
Eisai Inc.
Phase 3
1,069
California, Florida, Illinois, Kansas, Louisiana, Maryland, Massachusetts, Michigan
2016-10-13
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/renal-cell-carcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies listing the condition Renal Cell Carcinoma.

How many Renal Cell Carcinoma trials are recruiting in the US?

11 of the 27 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Renal Cell Carcinoma), 27 studies
PhaseStudiesRecruitingShare
Phase 112544.4%
Phase 35218.5%
Phase 1/24314.8%
Phase 23011.1%
Observational217.4%
Not applicable103.7%

Most active sponsors

Lead sponsors with the most studies (Renal Cell Carcinoma)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC52
Exelixis30
Bristol-Myers Squibb21
HiFiBiO Therapeutics20
AstraZeneca11
Daiichi Sankyo10
Deciphera Pharmaceuticals, LLC11
Eisai Inc.10
Fluidx Medical Technology, Inc.10
HiberCell, Inc.11

Top states

Top states (Renal Cell Carcinoma), by number of studies with a site there
StateStudies
California19
Florida10
New York10
Massachusetts9
Georgia8
Texas8
Illinois7
Michigan7
Pennsylvania7
Arizona6
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.